PT - JOURNAL ARTICLE AU - Matheus Filgueira Bezerra AU - Lais Ceschini Machado AU - Viviane do Carmo Vasconcelos de Carvalho AU - Cássia Docena AU - Sinval Pinto Brandão-Filho AU - Constância Flávia Junqueira Ayres AU - Marcelo Henrique Santos Paiva AU - Gabriel Luz Wallau TI - A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern AID - 10.1101/2021.03.20.21253956 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.20.21253956 4099 - http://medrxiv.org/content/early/2021/03/25/2021.03.20.21253956.short 4100 - http://medrxiv.org/content/early/2021/03/25/2021.03.20.21253956.full AB - The global spread of new SARS-CoV-2 variants of concern underscore an urgent need of simple deployed molecular tools that can differentiate these lineages. Several tools and protocols have been shared since the beginning of the COVID-19 pandemic, but they need to be timely adapted to cope with SARS-CoV-2 evolution. Although whole-genome sequencing (WGS) of the virus genetic material have been widely used, it still presents practical difficulties such as high cost, shortage of available reagents in the global market, need of a specialized laboratorial infrastructure and well-trained staff. These limitations result in genomic surveillance blackouts across several countries. Here we propose a rapid and accessible protocol based on Sanger sequencing of a single PCR fragment that is able to identify and discriminate all SARS-CoV-2 variants of concern (VOCs) identified so far, according to each characteristic mutational profile at the Spike-RBD region (K417N/T, E484K, N501Y, A570D). Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three from P.2, two from P.1 and seven from B.1.1 lineage. All results from the Sanger sequencing method perfectly matched the mutational profile of VOCs and non-VOCs described by WGS. In summary, this approach allows a much broader network of laboratories to perform molecular surveillance of SARS-CoV-2 VOCs and report results within a shorter time frame, which is of utmost importance in the context of rapid public health decisions in a fast evolving worldwide pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGabriel Luz Wallau was supported by the National Council for Scientific and Technological Development by the productivity research fellowship level 2 (303902/2019-1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Aggeu Magalhaes Institute's Ethical Commitee (Fiocruz-IAM), protocol number CAAE32333120.4.0000.5190.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomes generated in this study are deposited on GISAID under the accessions: EPI_ISL_500460, EPI_ISL_500461, EPI_ISL_500865, EPI_ISL_500868, EPI_ISL_500872, EPI_ISL_500477, EPI_ISL_500482, EPI_ISL_1239012, EPI_ISL_1239013, EPI_ISL_1239014, EPI_ISL_1239015, EPI_ISL_1239016 https://www.gisaid.org